However, since the beneficial cardiovascular effects of SGLT2 inhibitors in patients with T2DM were found to be primarily driven by a reduction in HF hospitalizations and the cardiovascular benefits exist independently of T2DM [31,32], the glycosuria effect seems to be too modest to explain the magnitude of the cardioprotective effect by itself [47,48,49,50]. Here, SLC5A2 is linked to type 2 diabetes mellitus.